Zoetis (NYSE:ZTS) Price Target Lowered to $104.00 at TD Cowen

Zoetis (NYSE:ZTS) had its target price decreased by equities researchers at TD Cowen from $150.00 to $104.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen’s price target would indicate a potential upside of 44.08% from the company’s previous close.

ZTS has been the subject of several other reports. Weiss Ratings lowered Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Morgan Stanley reaffirmed an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research report on Friday, May 15th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. JPMorgan Chase & Co. reduced their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, UBS Group lowered their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $130.85.

Zoetis Price Performance

Zoetis stock opened at $72.18 on Tuesday. The company’s 50 day simple moving average is $87.78 and its 200-day simple moving average is $110.59. The company has a market capitalization of $30.26 billion, a price-to-earnings ratio of 12.01, a price-to-earnings-growth ratio of 1.19 and a beta of 0.75. Zoetis has a 1 year low of $72.38 and a 1 year high of $161.77. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same period in the previous year, the business posted $1.48 EPS. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts expect that Zoetis will post 6.88 earnings per share for the current year.

Insider Transactions at Zoetis

In other Zoetis news, Director Frank A. Damelio bought 6,650 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 11,650 shares of company stock valued at $886,384. Corporate insiders own 0.22% of the company’s stock.

Hedge Funds Weigh In On Zoetis

A number of institutional investors have recently modified their holdings of ZTS. Global Wealth Strategies & Associates acquired a new position in Zoetis in the fourth quarter valued at $25,000. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis during the fourth quarter worth about $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in Zoetis during the 1st quarter valued at approximately $28,000. Lodestone Wealth Management LLC acquired a new stake in Zoetis during the 4th quarter worth approximately $30,000. Finally, Root Financial Partners LLC grew its stake in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.